WARNING: Market Shock Imminent

Join us on September 29 at 4 p.m. ET at the Market Shock 2022 event to find out what’s coming and how to profit.

Thu, September 29 at 4:00PM ET
 
 
 
 

Is Aurora Cannabis Stock a Buy?

ACB stock - Is Aurora Cannabis Stock a Buy?

Source: Ralf Liebhold / Shutterstock.com

The investors of Aurora Cannabis (NASDAQ:ACB) stock have been unimpressed by the pot company for quite some time now. ACB has been unprofitable and delivered results below expectations repeatedly in three of the last four quarters. ACB stock has declined 62% since the last year and is trading 68.5% below its 52-weeks high.

A series of unsuccessful acquisitions has overleveraged the company’s balance sheet and weighed down its top-line and bottom-line growth. As such management instigated cost curtailment initiatives to spur operating margins by shutting down some larger loss generating facilities. These efforts have stemmed earnings before interest, taxes, depreciation, and amortization (EBITDA) loss, which was $9 million in the second quarter of fiscal 2022. This is down from a loss of $80 million reported in Q2 fiscal 2020.

Total cost savings achieved from the initiative amounted to $60 million. This number is likely to reach $80 million by the first half of fiscal 2023.

The company’s, revenues however remain depressed, despite the operating costs and margins showings signs of improvement.

Management, in an effort to support growth, announced that it will acquire TerraFarma for $38 million. This will give ACB control of TerraFarma’s lucrative Thrive Cannabis brand. The deal is should close by the end of fiscal 2022. The transaction will strengthen the company’s capabilities in the Canadian markets and provide access to TerraFarma’s award-winning innovative premium products. These include dried flower, pre-rolls, vapor products and concentrates.

Aurora expects cost efficiencies gained from the acquisition should led to positive EBITDA by H1 fiscal 2023.

In addition to this, the marijuana industry is awaiting complete legalization of cannabis across the United States. Aurora should benefit from the industry tailwinds.

The pending acquisition of TerraFarma will strengthen the company’s footprints in Canada. It shall also better position ACB to cater to the larger market of the United States.

Declining ACB stock price has presented opportunities for long-term investment in the industry. The stock price should skyrocket.

On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.

Read More:Penny Stocks — How to Profit Without Getting Scammed

On the date of publication, Sakshi Agarwalla did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Sakshi Agarwalla has more than eight years of experience writing equity research reports and preparing financial models for companies across various industries, as well as writing newsletters and financial articles. Recently, she assisted her Fund manager in executing trades, preparing weekly, monthly NAVs and writing newsletters. She has a postgraduate degree in finance and has completed CFA.


Article printed from InvestorPlace Media, https://investorplace.com/2022/04/acb-stock-is-aurora-cannabis-a-buy/.

©2022 InvestorPlace Media, LLC